NZ744623A - Halo-substituted piperidines as orexin receptor modulators - Google Patents
Halo-substituted piperidines as orexin receptor modulatorsInfo
- Publication number
- NZ744623A NZ744623A NZ744623A NZ74462317A NZ744623A NZ 744623 A NZ744623 A NZ 744623A NZ 744623 A NZ744623 A NZ 744623A NZ 74462317 A NZ74462317 A NZ 74462317A NZ 744623 A NZ744623 A NZ 744623A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Claims (14)
1. A compound of formula (Ia), (Ia), or a pharmaceutically acceptable salt thereof, wherein: 5 X is F; X’ is F; Z is NR2 or O; A is pyridinyl, dinyl, pyrazinyl, pyridazinyl or benzoxazolyl, wherein A is ally substituted with one or more substituents independently ed from 10 the group consisting of alkyl, alkoxy, halo, -CHF2 and -CF3, n alkyl has from 1 to 4 carbon atoms, and wherein alkoxy is an alkyl group having an oxygen attached thereto wherein the alkyl group has from 1 to 4 carbon atoms; B is phenyl, nyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, thiazolyl, thiophenyl, pyrazolyl or benzoimidazolyl, 15 wherein B is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halo, alkoxy, –CN, -CH2CF3, -CHF2 and -CF3, wherein alkyl has from 1 to 4 carbon atoms, and wherein alkoxy is an alkyl group having an oxygen attached thereto wherein the alkyl group has from 1 to 4 carbon atoms; 20 E is phenyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, oxadiazolyl, pyrazinyl or pyrimidinyl, wherein E is optionally substituted with one or more substituents independently selected from the group ting of alkyl, halo, alkoxy, -CHF2 and -CF3, wherein alkyl has from 1 to 4 carbon atoms, and wherein alkoxy is an alkyl group having an oxygen ed thereto wherein the alkyl group has from 25 1 to 4 carbon atoms; n = 1; R1 is methyl; and R2 is H or alkyl, wherein alkyl has from 1 to 4 carbon atoms.
2. The compound of claim 1, wherein A is optionally substituted dinyl, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 or claim 2, wherein A is optionally substituted with one or more substituents independently selected from the list consisting of –F, -Br, -Cl, - CHF2, 5 -CF3, methyl, ethyl, and methoxy, or a pharmaceutically acceptable salt thereof.
4. The compound of any one of claims 1-3 wherein A is monosubstituted, or a pharmaceutically able salt thereof.
5. The nd of claim 4, wherein A is substituted with -CHF2 or -CF3, or a pharmaceutically acceptable salt thereof. 10
6. The compound of any one of claims 1-5, n B is optionally substituted with one or more substituents independently selected from the group consisting of -F, -Cl, -Br, -CN, methyl, ethyl, isopropyl, -CF3, -CH2CF3, isopropoxy, and methoxy, or a pharmaceutically acceptable salt thereof.
7. The compound of any one of claims 1-6, wherein B is monosubstituted, or a 15 pharmaceutically acceptable salt thereof.
8. The compound of claim 7, n B is substituted with methyl, or a pharmaceutically acceptable salt thereof.
9. The compound of any one of claims 1-8, wherein E is an optionally substituted pyrimidinyl, or a pharmaceutically acceptable salt thereof. 20
10. The compound of any one of claims 1-8, wherein E is an optionally tuted lyl, or a pharmaceutically acceptable salt thereof.
11. The compound of any one of claims 1-10, wherein E is optionally substituted with one or more -F, -Cl, -Br, methoxy, methyl, ethyl, –CF2H or –CF3, or a pharmaceutically acceptable salt f. 25
12. The compound of any one of claims 1-11, wherein E is optionally substituted with one or more methyl or -F, or a pharmaceutically acceptable salt f.
13. The compound of any one of claims 1-12, wherein Z is NH, or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1, wherein the compound selected from any one of the 30 following: Compound Compound nd Compound # # 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16 N F HN CF3 F N N O 17 24 18 25 N F HN CF3 F N N O 19 26 20 27 21 28 22 29 23 30 31 38 32 39 33 N 40 F HN CF3 F N N O 34 N 41 F HN Cl F N N O 35 42 N F HN CF3 F N N O N N 36 43 37 44 45 53 46 54 47 55 48 56 49 57 50 58 N F HN CF3 F N 51 59 52 60 61 68 62 69 63 70 64 71 65 72 N F HN CF3 F N N O 66 73 67 74 75 82 76 83 77 84 N F HN CF3 F N N O 78 85 79 86 80 87 81 88 89 97 90 98 91 99 92 93 94 102 95 103 96 104 105 112 106 113 107 114 OMe F HN CF3 F N N O 108 115 109 116 110 117 111 118 119 126
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294940P | 2016-02-12 | 2016-02-12 | |
| US201662336102P | 2016-05-13 | 2016-05-13 | |
| PCT/US2017/017408 WO2017139603A1 (en) | 2016-02-12 | 2017-02-10 | Halo-substituted piperidines as orexin receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ744623A true NZ744623A (en) | 2025-03-28 |
| NZ744623B2 NZ744623B2 (en) | 2025-07-01 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200274T1 (en) | Therapeutically active compounds and their methods of use | |
| AR074426A1 (en) | COMPOSITE OF N - (((1S, 4S, 6S) -3- (2-PIRIDINILCARBONIL) 3-AZABICICLO (4,1.0) HEPT-4-IL) METHYL) -2-HETEROARYLAMINE, ITS USE FOR THE PREPRATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A DISEASE THAT REQUIRES AN ANTAGONIST OF A RECEIVER OF HUMAN OREXIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS | |
| PE20141067A1 (en) | COMPOUNDS FOR THE TREATMENT OF ADDICTION | |
| IL303962B1 (en) | Substituted naphthyridine-urea compounds and a medicine comprising the compound | |
| WO2009051956A3 (en) | Pyrazole-substituted isoxazoline insecticides | |
| JP2019533694A5 (en) | ||
| RU2007146115A (en) | HETEROCYCLIC MEK INHIBITORS AND WAYS OF THEIR APPLICATION | |
| SI2800743T1 (en) | Therapeutically active compounds and their methods of use | |
| NZ603198A (en) | Novel hydroxamic acid derivative | |
| JP2016528201A5 (en) | ||
| CA2450922A1 (en) | Piperidines for use as orexin receptor antagonists | |
| JP2019503342A5 (en) | ||
| NZ609955A (en) | Sgc stimulators | |
| JP2013505903A5 (en) | ||
| PH12015501929A1 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| AR089134A1 (en) | ARILOS AND INHIBITING BICYCLE HETEROARILS OF THE SODIUM CHANNELS | |
| NZ717119A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| SI2509955T1 (en) | Pyrazole derivatives as modulators of calcium release-activated calcium channel | |
| HRP20161011T1 (en) | ARYL DIHYDROPYRIDINONES AND PIPERIDINONES AS MGAT2 INHIBITORS | |
| JP2013505263A (en) | Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of formation and use thereof | |
| MX2015014406A (en) | Fungicidal carboxamides. | |
| AR082827A1 (en) | ARIL-METILOXI-BENZAMIDA COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR PROFILAXIS OF PARKINSON'S DISEASE | |
| MX2009000110A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases. | |
| HRP20220906T1 (en) | Halo-substituted piperidines as orexin receptor modulators | |
| JP2025501721A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |